6,170 Shares of Gilead Sciences, Inc. $GILD Bought by TSG Advice Partners LLC

TSG Advice Partners LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,170 shares of the biopharmaceutical company’s stock, valued at approximately $920,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of Nova Scotia acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $100,056,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Gilead Sciences during the 2nd quarter worth $55,754,000. Groupe la Francaise grew its holdings in shares of Gilead Sciences by 30.9% during the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after purchasing an additional 11,712 shares during the period. Baird Financial Group Inc. increased its position in shares of Gilead Sciences by 3.6% during the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $6,251,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 0.2%

NASDAQ GILD opened at $170.33 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market cap of $211.20 billion, a price-to-earnings ratio of -53.90 and a beta of 0.31. The firm has a 50 day simple moving average of $151.36 and a 200-day simple moving average of $140.03. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $175.65.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.47 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post -1.03 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is -103.80%.

Analyst Ratings Changes

Several brokerages recently issued reports on GILD. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Truist Financial increased their target price on shares of Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a research note on Friday. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research report on Friday. Scotiabank lifted their price target on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research report on Friday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a research note on Friday. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $169.74.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead said it will present late-breaking clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026 on November 8–11. Updates on HIV therapies, its development pipeline and strategic collaborations could provide catalysts if the results reinforce the company’s leadership in HIV treatment. Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
• Positive Sentiment: Analysts have raised several Gilead price targets, including targets of $175, $181, $183, $188, $190 and $200. Separately, an updated fair-value estimate rose from $158.65 to $165.31, reflecting improved views of third-quarter execution, the HIV business and pipeline assets. Gilead Sciences Price Target Raised to $200.00 Gilead Stock Fair Value Edges Higher After Analyst Target Increases
• Positive Sentiment: Gilead continues to receive favorable analyst attention, including a Morgan Stanley Buy rating and inclusion among healthcare stocks described as having Strong Buy ratings and high quantitative scores. Gilead Sciences Receives a Buy from Morgan Stanley
• Neutral Sentiment: Former Gilead U.S. Medical Affairs head Dean Hakanson joined GOA Therapeutics as chief medical officer. The move highlights executive experience gained at Gilead, but it does not directly change Gilead’s operations or financial outlook. Former Gilead Head of U.S. Medical Affairs Joins GOA Therapeutics
• Negative Sentiment: One recent earnings analysis characterized Gilead’s outlook as mixed: revenue guidance was raised, but the EPS outlook worsened. That contrast could limit upside by raising concerns about profitability even as the HIV business remains strong. Gilead Sciences Q3 2026 Earnings Analysis

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00. Following the transaction, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at $93,642,672.42. The trade was a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 126,881 shares of company stock valued at $19,252,455. Insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.